Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Athena is also exploring the use of this technology for expanded carrier screening
This will be Aster’s fifth hospital in Bengaluru
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
cSCC is one of the most common cancers in the U.S. and globally
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
Subscribe To Our Newsletter & Stay Updated